Qualigen Therapeutics is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases


The US ppatent and trademark office. (Credit: Coolcaesar/Wikipedia.)

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today that the United States Patent and Trademark Office has issued patent No. 10,744,257 entitled “Devices and Methods for On-Line Whole Blood Treatment” regarding the Company’s Selective Target Antigen Removal System (STARS™) technology.

STARS is a DNA/RNA-based treatment device candidate for the removal of viral and tumor-produced compounds from a patient’s blood.  The STARS technology utilizes a filtration cartridge designed for use in a standard dialysis machine, and contains aptamer-coated microparticles that bind to specific agents in circulating blood for targeted removal.

“This patent strengthens our intellectual property portfolio and increases our number of issued patents to 26, or 45 including jointly held patents. Our strategy is to continue to protect our proprietary technologies in the U.S. and globally,” said Michael Poirier, President, Chief Executive Officer and Chairman of Qualigen.  “Although STARS is in the early stages of development, our in vitro studies have demonstrated encouraging proof-of-concept results and we look forward to advancing this program as a target-and-removal therapy for a broad range of diseases.”

The STARS development program utilizes technology and expertise from the Company’s FastPack® point-of-care diagnostic system, which has been in use worldwide for nearly 20 years for the detection of cancer and other diseases.  The Company plans to develop STARS for cancer applications to remove inflammatory factors and inhibitory checkpoints from blood, thus reducing pain and helping the body’s immune system fight the disease, as well as for infectious diseases to remove viruses and other foreign agents.

Source: Company Press Release